Investors
A proven track record of value creation
Our robust business model provides significant opportunities to drive growth and deliver value for investors.
Together we’re building a leading global pharmaceutical business
By putting better health within reach of patients every day through investment, innovation and diversification, we’re enhancing our portfolio responsibly and creating strong shareholder returns.
H1 2025 Interim Results
Watch Riad Mishlawi, CEO
Latest stories
Featured
Hikma delivers a solid H1 performance and re-affirms expectations for strong growth in the second half
Press Release, Financial Results
07 August 2025
- Hikma R&D - Innovating formulation development: Meet Mihir Modh Story, Life at Hikma 26 August 2025 Hikma R&D - Innovating formulation development: Meet Mihir Modh
- Acting responsibly for purpose-driven impact: How Hikma champions inclusive education Insight, Responsibility 25 August 2025 Acting responsibly for purpose-driven impact: How Hikma champions inclusive education
- Inspiring women of Hikma - Meet Dr Nina Diaz, General Manager of Hikma Thymoorgan, Germany Story, Leadership 22 August 2025 Inspiring women of Hikma - Meet Dr Nina Diaz, General Manager of Hikma Thymoorgan, Germany
- Strategic insights into Hikma Injectables CMO: meeting partner expectations Insight, Corporate 14 August 2025 Strategic insights into Hikma Injectables CMO: meeting partner expectations
